Tirzepatide Program
Explore a clinician-guided tirzepatide program through Vea Health. Eligibility, formulation and dosing are determined by the treating provider.
- Medical review required
- Telehealth-based evaluation
- Prescription only if appropriate
2026 Evidence Guide
Best Peptides for Weight Loss: What the Evidence Actually Supports
Compare tirzepatide, semaglutide and other peptide-based approaches without the hype. Learn which options have strong clinical evidence, what compounded treatment means, and when clinician-guided care matters.
Prescription treatment is subject to medical evaluation. Not everyone qualifies.
Clinician-Guided Options
Explore Vea Health Weight-Loss Programs
The links below are affiliate links. Vea states that provider approval is required and that its compounded medications are not FDA-approved.
Semaglutide Program
Explore Vea Health's clinician-guided semaglutide option. A licensed provider determines whether treatment is medically appropriate.
- Provider approval required
- Telehealth evaluation
- Follow-up based on provider plan
Tirzepatide Microdosing
Vea also markets a tirzepatide microdosing program. Evidence for GLP-1 “microdosing” as a distinct weight-loss strategy is less established than evidence for labeled regimens of FDA-approved products.
Explore Tirzepatide Microdosing →Semaglutide Microdosing
Vea also offers a semaglutide microdosing pathway. Patients should discuss the evidence, potential benefits, risks and dosing rationale with the prescribing clinician.
Explore Semaglutide Microdosing →Important distinction: branded products such as Zepbound (tirzepatide) and Wegovy (semaglutide) have FDA-approved indications. Compounded semaglutide or tirzepatide products are not FDA-approved and should not be described as generic or as equivalent to FDA-approved products.
At a Glance
Tirzepatide vs. Semaglutide vs. Other Peptides
The strongest evidence for clinically meaningful weight reduction is concentrated in GLP-1–based medications studied in large randomized trials.
| Compound | How it works | Weight-loss evidence | Key point |
|---|---|---|---|
| Tirzepatide | GIP + GLP-1 receptor agonist | Extensive randomized-trial evidence for branded Zepbound | FDA-approved branded product exists for chronic weight management in eligible adults. |
| Semaglutide | GLP-1 receptor agonist | Extensive randomized-trial evidence for branded Wegovy | FDA-approved branded product exists for chronic weight management in eligible patients. |
| CJC-1295 / Ipamorelin | Growth-hormone secretagogue pathway | Mechanistic rationale; far less direct human weight-loss evidence | Should not be presented as equivalent to GLP-1 weight-loss therapies. |
| AOD-9604 / BPC-157 | Different metabolic or tissue-repair pathways | Insufficient robust human evidence for standalone weight loss | Marketing claims should remain conservative. |
Evidence First
How Peptide-Based Weight-Loss Treatments Differ
“Peptide” is a broad term. Different compounds act through different biological pathways, so evidence from one peptide cannot automatically be applied to another. GLP-1 receptor agonists act on receptors involved in appetite, satiety and gastric emptying. Tirzepatide additionally targets the GIP receptor.
Why tirzepatide and semaglutide stand apart
Specific branded formulations of tirzepatide and semaglutide have been studied in large randomized clinical trials and have FDA-approved uses for chronic weight management. That level of evidence is substantially stronger than the human weight-loss evidence available for compounds such as CJC-1295, AOD-9604 and BPC-157.
Why product type matters
A drug's active ingredient is only part of the picture. FDA approval applies to a specific product, manufacturing process, formulation, labeling and indication. Compounded drugs may be prescribed in certain circumstances, but they do not undergo FDA premarket review for safety, effectiveness or quality.
Safety
Medical Screening Is Part of the Treatment
These are prescription treatments, not ordinary supplements. A clinician should review relevant medical history, medications, contraindications and potential side effects before treatment.
Common considerations
GLP-1–based medications commonly cause gastrointestinal effects such as nausea, vomiting, diarrhea or constipation, especially during dose escalation. Individual risk varies.
Who may not qualify
Product labeling and clinical guidance include important contraindications and warnings. Pregnancy, certain thyroid-cancer histories, MEN 2, hypersensitivity and other conditions can affect eligibility. A provider should make the determination.
FAQ
Common Questions
What peptides have the strongest evidence for weight loss?
Among peptide-based prescription medications, branded tirzepatide and semaglutide products have extensive randomized clinical-trial evidence for weight management. Other peptides are often discussed online, but their direct human evidence for meaningful weight reduction is substantially weaker.
Are compounded semaglutide and tirzepatide FDA-approved?
No. FDA states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before they are marketed.
Is compounded medication the same as a generic?
No. FDA-approved generic drugs must meet FDA requirements. Compounded drugs are not FDA-approved generics and should not be marketed as the same as an approved product.
What is GLP-1 microdosing?
The term generally refers to using amounts below conventional treatment or maintenance regimens. The evidence base for microdosing specifically as a weight-loss strategy is less established than the evidence supporting labeled regimens of FDA-approved products. A licensed clinician should determine dosing.
Do I need a prescription?
Semaglutide and tirzepatide are prescription medications. Legitimate treatment requires evaluation and prescribing by an appropriately licensed clinician.
Sources & further reading
This page is educational and was prepared using FDA information and the clinical-evidence summary provided for this site. For current regulatory and safety information, see the FDA's compounding Q&A, the FDA's information on unapproved GLP-1 drugs, and official FDA labeling for approved products.